[
  {
    "ts": null,
    "headline": "Is Cardinal Health (CAH) Stock Undervalued Right Now?",
    "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
    "url": "https://finnhub.io/api/news?id=5f7ef85d003aab0103c34c36357f5837ce3351a8af42fec3480653940230730b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611204,
      "headline": "Is Cardinal Health (CAH) Stock Undervalued Right Now?",
      "id": 138285425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
      "url": "https://finnhub.io/api/news?id=5f7ef85d003aab0103c34c36357f5837ce3351a8af42fec3480653940230730b"
    }
  },
  {
    "ts": null,
    "headline": "PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results",
    "summary": "Phibro Animal Health heads into Q2 with strong Animal Health momentum, revenues up 15.4% and EPS up 27.8%, as MFA, nutrition and vaccines drive results",
    "url": "https://finnhub.io/api/news?id=eee53b960d5d73778f9d3ca39fd162f936868746bd44575bbc5da80fbbf5f741",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604360,
      "headline": "PAHC Q2 Earnings Preview: Animal Health Momentum Likely to Aid Results",
      "id": 138281725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Phibro Animal Health heads into Q2 with strong Animal Health momentum, revenues up 15.4% and EPS up 27.8%, as MFA, nutrition and vaccines drive results",
      "url": "https://finnhub.io/api/news?id=eee53b960d5d73778f9d3ca39fd162f936868746bd44575bbc5da80fbbf5f741"
    }
  },
  {
    "ts": null,
    "headline": "Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings",
    "summary": "Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water gains.",
    "url": "https://finnhub.io/api/news?id=35ec9c039aeab8d0a5d43ee4cf116bc235eeb5efc226b5418494593156f9bc81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604180,
      "headline": "Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings",
      "id": 138281713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Ahead of Q4 earnings, IDXX eyes double-digit revenue and EPS growth, driven by CAG momentum, new diagnostics and steady Water gains.",
      "url": "https://finnhub.io/api/news?id=35ec9c039aeab8d0a5d43ee4cf116bc235eeb5efc226b5418494593156f9bc81"
    }
  },
  {
    "ts": null,
    "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
    "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
    "url": "https://finnhub.io/api/news?id=6b8a19271e13128fe728d51e5b8d54bebed410a56a5e704297fc82c93e769414",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769603220,
      "headline": "Will Robust MedSurg Performance Fuel Boston Scientific's Q4 Earnings?",
      "id": 138281612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "BSX heads into Q4 earnings with strong MedSurg momentum and Cardiovascular growth, as revenue and EPS estimates point to double-digit gains.",
      "url": "https://finnhub.io/api/news?id=6b8a19271e13128fe728d51e5b8d54bebed410a56a5e704297fc82c93e769414"
    }
  },
  {
    "ts": null,
    "headline": "STERIS' Q3 Earnings on Deck: What's in Store for the Stock?",
    "summary": "STE enters Q3 earnings with revenues seen up 8% to $1.48B and EPS rising 9.1% to $2.53, supported by strength in Healthcare, AST and Life Sciences.",
    "url": "https://finnhub.io/api/news?id=bf5ac14318f0ff953e04437cf51c169f48079cf2e9046dc234feced6053ce948",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769603160,
      "headline": "STERIS' Q3 Earnings on Deck: What's in Store for the Stock?",
      "id": 138281728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "STE enters Q3 earnings with revenues seen up 8% to $1.48B and EPS rising 9.1% to $2.53, supported by strength in Healthcare, AST and Life Sciences.",
      "url": "https://finnhub.io/api/news?id=bf5ac14318f0ff953e04437cf51c169f48079cf2e9046dc234feced6053ce948"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Cardinal Health: “I Can See That Stock Going to $300”",
    "summary": "Cardinal Health, Inc. (NYSE:CAH) is one of the stocks Jim Cramer discussed, along with market shortages. Mentioning that they like the company, a caller asked for Cramer’s take on it, and he replied: Oh, Jason Hollar. You know it’s funny… I’m out there. You got all these great drug companies, and who am I most […]",
    "url": "https://finnhub.io/api/news?id=11322e01d0816466ffd79ef79a85f478ad5565e3cb60d1c402faf7d58fd74c0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769602993,
      "headline": "Jim Cramer on Cardinal Health: “I Can See That Stock Going to $300”",
      "id": 138280840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Cardinal Health, Inc. (NYSE:CAH) is one of the stocks Jim Cramer discussed, along with market shortages. Mentioning that they like the company, a caller asked for Cramer’s take on it, and he replied: Oh, Jason Hollar. You know it’s funny… I’m out there. You got all these great drug companies, and who am I most […]",
      "url": "https://finnhub.io/api/news?id=11322e01d0816466ffd79ef79a85f478ad5565e3cb60d1c402faf7d58fd74c0f"
    }
  }
]